HVR Cardio, a designer and developer of cardiovascular devices, is developing a breakthrough solution for mitral valve repair based on its proprietary helical technology. The company’s main products, CathHELIX and MAR, are transcatheter and surgical mitral valve repair devices designed to overcome the adverse effects of mitral regurgitation on the human body. Recently, it announced the completion of the B-round financing of 10.7 million euros. The round was led by Finland-based Innovestor Life Science Fund and Tesi. Meanwhile, HVR Cardio has announced its new leadership team, hiring Tom Fleming as CEO.
This article is transferred from: https://www.itjuzi.com/investevent/13780486
This site is only for collection, and the copyright belongs to the original author.